The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

The U.S. Food and Drug Administration has approved Zoryve (roflumilast) topical foam 0.3 percent for the treatment of plaque ...

That's where a salicylic acid shampoo comes in. Like a dandruff shampoo, these formulas can help relieve dryness, flakes, and itchiness associated with the condition–but salicylic acid takes the scalp ...

Stull said that a number of prescription treatments exist for topical psoriasis, such as steroids and injectable therapies, but there are also over-the-counter products that can h ...

evaluated the safety and efficacy of icotrokinra in 311 adults and adolescents 12 years of age and older with plaque psoriasis affecting the scalp, genital area, and/or palms of the hands and ...

Johnson & Johnson (J&J) has reported new data from the Phase III ICONIC-TOTAL trial, which evaluated icotrokinra, an oral peptide, in treating plaque ... having scalp and genital psoriasis ...

Data from icotrokinra ICONIC-TOTAL show 66% of patients with scalp psoriasis and 77% with ... area as low as 1% and at least moderate plaque psoriasis (PsO) affecting high-impact skin sites.

Accessed May 2025. 7 Clinicaltrials. A study of JNJ-2113 for the treatment of participants with plaque psoriasis involving special areas (scalp, genital, and/or palms of the hands and the soles of ...

Findings indicated significantly higher rates of clinical improvement in scalp and body lesions among those receiving the active treatment compared to a placebo. Plaque psoriasis, a chronic ...

Once-daily roflumilast foam, 0.3% (Zoryve) significantly improved scalp and body symptoms of plaque psoriasis in a phase III trial. Improvements in scalp itch were also greater for patients ...

Once-daily 0.3% topical roflumilast foam significantly reduced severity in patients with psoriasis of the scalp and body over 8 weeks, with a favorable safety profile. “Use of roflumilast foam ...